Rizzo Alessandro, Ricci Angela Dalia, Di Federico Alessandro, Frega Giorgio, Palloni Andrea, Tavolari Simona, Brandi Giovanni
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Front Oncol. 2021 Dec 17;11:803133. doi: 10.3389/fonc.2021.803133. eCollection 2021.
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely evaluated and are under assessment, as monotherapy or in combination with other anticancer agents in treatment-naïve and previously treated patients. In particular, the approval of the PD-L1 inhibitor atezolizumab plus the antiangiogenic agent bevacizumab as front-line treatment for advanced HCC has led to the adoption of this combination in this setting, and the IMbrave 150 phase III trial has established a novel standard of care. However, several questions remain unanswered, including the identification of reliable predictors of response to ICIs in HCC patients. In the current paper, we will provide an updated overview of potentially useful predictive biomarkers of response to immunotherapy in advanced HCC. A literature search was conducted in September 2021 of Pubmed/Medline, Cochrane library and Scopus databases.
肝细胞癌（HCC）仍然是全球第六大最常被诊断出的恶性肿瘤，仍是癌症相关死亡的一个重要原因。在接下来的几年里，出现了新的全身治疗选择。其中，免疫检查点抑制剂（ICIs）已得到广泛评估并正在接受评估，作为单药治疗或与其他抗癌药物联合用于初治和既往接受过治疗的患者。特别是，PD-L1抑制剂阿替利珠单抗联合抗血管生成药物贝伐单抗被批准作为晚期HCC的一线治疗方案，这使得该联合方案在这种情况下被采用，并且IMbrave 150 III期试验确立了一种新的护理标准。然而，仍有几个问题未得到解答，包括确定HCC患者对ICIs反应的可靠预测指标。在本文中，我们将提供晚期HCC中免疫治疗反应潜在有用预测生物标志物的最新概述。2021年9月在Pubmed/Medline、Cochrane图书馆和Scopus数据库中进行了文献检索。
